Genmab

Corporate Details

ISIN(s):

DK0010272202 (+2 more)

LEI:

529900MTJPDPE4MHJ122

Country:

Denmark

Address:

Carl Jacobsens Vej 30, 2500 Valby

Website:

https://www.genmab.com/

Sector:

Professional, scientific and technical activities

Industry:

Research and experimental development on natural sciences and engineering

Description

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. We are the creators of three marketed products* and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.